DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.69
0.00 (0.00%)
Oct 28, 2026, 9:34 AM EDT - Market open
DiaMedica Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, DiaMedica Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $15.5. The average 1-year stock price forecast is 78.37% higher than the current stock price, while the lowest is $11 (+26.58%) and the highest is $25 (+187.69%).
Price Target: $15.5 (+78.37%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 22, 2026.
Analyst Ratings
The average analyst rating for DiaMedica Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $12 | Buy | Maintains | $12 | +38.09% | Sep 22, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 25, 2026 |
| Lake Street | Lake Street | Buy Reiterates $14 | Buy | Reiterates | $14 | +61.10% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.81
from -0.70
EPS Next Year
-0.75
from -0.81
EPS and Forward PE are based on non-GAAP adjusted numbers.